IVA (IVA) Stock Price & Analysis
IVA (IVA) rose 1.53% to USD 3.97 as of June 10, 2026 at 07:32 UTC, according to Nexqual real-time market data.
IVA last closed at USD 3.91; the session ranged USD 3.7–4.02 on volume of 972,900 shares. Market capitalization is $829.52M, with a 52-week range of USD 2.85–7.98 (NGM). Source: Nexqual, June 10, 2026 at 07:32 UTC.
Key Statistics (as of June 10, 2026 at 07:32 UTC)
| Price | USD 3.97 |
|---|---|
| Change | ▲ 1.53% (up) |
| Previous Close | USD 3.91 |
| Open | USD 4 |
| Day Range | USD 3.7 – 4.02 |
| 52-Week Range | USD 2.85 – 7.98 |
| Volume | 972,900 shares |
| Market Cap | $829.52M |
| Exchange | NGM |
Technical Analysis (IVA)
Nexqual's technical model rates IVA "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:32 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.61 (oversold) |
| vs SMA50 | Below (USD 5.2) |
| MACD | -0.35 (negative) |
Analyst Ratings (IVA)
Wall Street analysts rate IVA "Strong Buy" based on 13 analysts, with a mean price target of USD 15.13 (range USD 8.8–26), per Nexqual as of June 10, 2026 at 07:32 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 15.13 |
| High Target | USD 26 |
| Low Target | USD 8.8 |
| Buy / Hold / Sell | 13 / 0 / 0 |
Earnings (IVA)
| Next Earnings Date | 2026-03-30 |
|---|---|
| EPS Estimate | USD -0.23 |
| Revenue Estimate | $0 |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financials & Fundamentals (IVA)
| Total Revenue | $6.76M |
|---|---|
| Revenue Growth (YoY) | -89.90% |
| Gross Margin | +99.68% |
| Operating Margin | -6710.69% |
| Profit Margin | +0.00% |
| Current Ratio | 3.16 |
| Total Cash | $99.84M |
| Total Debt | $230.89M |
| Free Cash Flow | $-200.71M |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financial Health Score (IVA)
Nexqual rates IVA's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:32 UTC.
| Growth | Critical — Revenue -51% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $100M cash vs $231M debt |
| Cash Flow | Weak — FCF negative: -$201M, burning cash |
| Efficiency | Mixed — No data |
Ownership (IVA)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +25.64% |
| Shares Outstanding | 208.95M |
| Float | 154.23M |
| Short % of Float | +0.35% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Leadership (IVA)
IVA is led by Andrew Obenshain (age 51), Chief Executive Officer, per Nexqual as of June 10, 2026 at 07:32 UTC.
| Chief Executive Officer | Andrew Obenshain (age 51) |
|---|---|
| President of Research & Development and Chief Medical Officer | Jason A. Campagna (age 59) |
| Chief Financial Officer | Axel-Sven Malkomes (age 58) |
| Executive Vice President of External and Corporate Affairs | Pascaline Clerc (age 45) |
Major Backers & Investors (IVA)
Notable institutional backers of IVA include Samsara BioCapital, LLC, Caligan Partners, LP, Paradigm Biocapital Advisors LP, according to Nexqual as of June 10, 2026 at 07:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Samsara BioCapital, LLC | 2.49% |
| Caligan Partners, LP | 2.38% |
| Paradigm Biocapital Advisors LP | 1.91% |
| Millennium Management | 1.43% |
| Trails Edge Capital Partners, LP | 1.27% |
| Franklin Resources, Inc. | 1.18% |
| SymBiosis Capital Partners, LLC | 1.13% |
| UBS Group AG | 1.11% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANNX | Annexon, Inc. | USD 5.2 | ▼ 1.7% |
| NBTX | Nanobiotix S.A. | USD 34.34 | ▼ 3.16% |
| IPHA | Innate Pharma S.A. | USD 1.77 | ▲ 3.51% |
| INBX | Inhibrx Biosciences, Inc. | USD 89.1 | ▲ 2.4% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.37 | ▼ 4.46% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:32 UTC. This page is informational and not investment advice.